2022
Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection
Dalgard O, Litwin AH, Shibolet O, Grebely J, Nahass R, Altice FL, Conway B, Gane EJ, Luetkemeyer AF, Peng CY, Iser D, Gendrano IN, Kelly MM, Haber BA, Platt H, Puenpatom A. Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection. Journal Of Addictive Diseases 2022, 41: 213-224. PMID: 35920743, DOI: 10.1080/10550887.2022.2088978.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmidesAnalgesics, OpioidAntiviral AgentsHepacivirusHepatitis C, ChronicHumansQuality of LifeConceptsElbasvir/grazoprevirHepatitis C virus infectionC virus infectionOpioid agonist therapyHealth-related qualityEnd of treatmentHCV infectionAgonist therapyVirus infectionChronic hepatitis C virus (HCV) infectionImproved health-related qualityMental component summary scoresTreatment week 4Placebo-controlled studyOpioid agonist treatmentMedical Outcomes StudyComponent summary scoresSF-36v2 scoresTreatment differencesImproved HRQOLViral eradicationActing antiviralsOpioid dependenceAgonist treatmentGeneral health
2021
Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients
Sivakumar A, Madden L, DiDomizio E, Eller A, Villanueva M, Altice FL. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. International Journal Of Drug Policy 2021, 101: 103570. PMID: 34954493, PMCID: PMC8685180, DOI: 10.1016/j.drugpo.2021.103570.Peer-Reviewed Original ResearchConceptsOpioid use disorderHepatitis C virusSyringe services programDifferentiated care modelPerson visitsC virusCare modelUse disordersInitiation of DAAChronic HCV infectionEvidence-based treatmentsCOVID-19Initial phlebotomyVirological responseHCV infectionHCV treatmentAdditional patientsElevated riskPatientsClient-centred approachPWIDHIVPerson contactTreatment demandLaboratory screening
2020
Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States
Zelenev A, Li J, Shea P, Hecht R, Altice FL. Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States. Clinical Infectious Diseases 2020, 72: 755-763. PMID: 32060534, PMCID: PMC7935393, DOI: 10.1093/cid/ciaa142.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsConnecticutHepacivirusHepatitis CHumansPharmaceutical PreparationsSubstance Abuse, IntravenousUnited StatesConceptsOpioid agonist therapySyringe services programHepatitis C virus (HCV) treatmentC virus treatmentHCV prevalenceHCV microeliminationHCV TasPHCV treatmentPrevention strategiesVirus treatmentTasP strategyHigh HCV prevalenceMicroelimination of HCVHuman immunodeficiency virusHCV treatment coverageOAT coverageAgonist therapyImmunodeficiency virusTreatment coverageMicroeliminationPrevention impactPrevalenceComplimentary interventionsHCVPWID
2019
Staying hepatitis C negative: A systematic review and meta‐analysis of cure and reinfection in people who inject drugs
Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, Li Z, Pedrana A, Gottfredsson M, Bouscaillou J, Luhmann N, Mazhnaya A, Altice FL, Saeed S, Klein M, Falade‐Nwulia O, Aspinall E, Hutchinson S, Hellard ME, Sacks‐Davis R. Staying hepatitis C negative: A systematic review and meta‐analysis of cure and reinfection in people who inject drugs. Liver International 2019, 39: 2244-2260. PMID: 31125496, DOI: 10.1111/liv.14152.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsDrug UsersHepatitis CHumansMedication AdherenceOpiate Substitution TreatmentSustained Virologic ResponseConceptsSustained viral responseDirect-acting antiviralsRecent PWIDOST recipientsTreatment discontinuationPerson yearsReinfection rateRelative riskTreatment outcomesSystematic reviewIncidence of reinfectionTreatment discontinuation ratesPooled relative riskHepatitis C treatmentNewcastle-Ottawa ScaleMixed effects linear modelTherapy recipientsDiscontinuation ratesHepatitis C.Pooled incidenceViral responseCure rateRecent injectingStudy qualityPWIDThe accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis
Serfaty L, Jacobson I, Rockstroh J, Altice FL, Hwang P, Barr E, Robertson M, Haber B. The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis. Journal Of Viral Hepatitis 2019, 26: 329-336. PMID: 30412325, DOI: 10.1111/jvh.13037.Peer-Reviewed Original ResearchMeSH KeywordsAmidesAntiviral AgentsBenzofuransCarbamatesCyclopropanesData Interpretation, StatisticalFemaleGenotypeHepacivirusHepatitis C, ChronicHumansImidazolesMalePredictive Value of TestsQuinoxalinesReproducibility of ResultsSensitivity and SpecificitySulfonamidesSustained Virologic ResponseViral LoadConceptsBaseline viral loadResistance-associated substitutionsNS5A resistance-associated substitutionsEBR/GZRElbasvir/grazoprevirGenotype 1a infectionViral loadNegative predictive valuePositive predictive valuePredictive valueBaseline NS5a resistance-associated substitutionsHepatitis C virus infectionPoor negative predictive valueEuropean treatment guidelinesC virus infectionSustained virologic responseHigh positive predictive valueEBR 50GT1a infectionVirologic failureVirologic responseTreatment guidelinesTreatment outcomesVirus infectionStratification factors
2018
Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era
Sacks‐Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME. Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era. Journal Of The International AIDS Society 2018, 21: e25051. PMID: 29633559, PMCID: PMC5978682, DOI: 10.1002/jia2.25051.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsCoinfectionContinuity of Patient CareDelivery of Health CareDisease EradicationHepatitis CHIV InfectionsHumansConceptsCo-infected populationHIV co-infected populationElimination initiativeHCV eliminationHIV/HCV co-infected populationCare dataHCV treatment uptakeSustained virological responseHalf of patientsDAA eraDAA treatmentHCV careSVR ratesVirological responseHCV infectionHCV treatmentHCV RNAImplementation science frameworkTreatment uptakeHigh-income countriesHIVIntervention characteristicsTreatment availabilityDiagnosis rateElimination program
2017
Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study
Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. The Lancet Infectious Diseases 2017, 18: 215-224. PMID: 29153265, PMCID: PMC5860640, DOI: 10.1016/s1473-3099(17)30676-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntiviral AgentsChemopreventionCitiesComputer SimulationDisease Transmission, InfectiousFemaleHepatitis CHumansMaleMiddle AgedModels, StatisticalPrevalenceSubstance Abuse, IntravenousSurveys and QuestionnairesTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsBaseline HCV prevalenceHepatitis C virusHCV prevalenceInjection partnersPrevention strategiesTreatment coverageTransmission of HCVHepatitis C virus (HCV) treatmentHCV elimination strategySuccessful HCV treatmentC virus treatmentInjection drug usersHCV treatment coverageAdditional network memberHCV treatmentActing antiviralsC virusChronic infectionVirus treatmentDrug usersPrevalenceDrug abuseDrugsNational InstitutePreventionImplementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes
Mazhnaya A, Meteliuk A, Barnard T, Zelenev A, Filippovych S, Altice FL. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes. International Journal Of Drug Policy 2017, 47: 187-195. PMID: 28811159, PMCID: PMC5918282, DOI: 10.1016/j.drugpo.2017.07.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCoinfectionFemaleGenotypeHealth ServicesHepacivirusHepatitis CHIV InfectionsHumansInterferon-alphaMalePolyethylene GlycolsProgram DevelopmentProgram EvaluationRecombinant ProteinsRibavirinRisk FactorsSex FactorsSofosbuvirSubstance Abuse, IntravenousSustained Virologic ResponseTreatment OutcomeUkraineYoung AdultConceptsSustained virologic responseHCV treatmentRisk groupsSVR ratesMedical recordsDirect acting antiviral medicationsComparable SVR ratesHCV genotype 3HCV prevalence estimatesHCV treatment servicesActing antiviral (DAA) medicationsCombination of sofosbuvirHigh-risk groupPatient-level outcomesProportion of participantsCommunity-based settingsDAA treatmentVirologic responseAntiviral medicationsHIV characteristicsHCV genotypesIndependent correlatesSVR dataFemale sexGenotype 3
2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Annals Of Internal Medicine 2016, 165: 625-634. PMID: 27537841, DOI: 10.7326/m16-0816.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntiviral AgentsBenzofuransBuprenorphineBuprenorphine, Naloxone Drug CombinationDouble-Blind MethodDrug CombinationsDrug Resistance, ViralFemaleGenotypeHepatitis C, ChronicHumansImidazolesMaleMedication AdherenceMethadoneMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersQuinoxalinesRecurrenceSubstance Abuse, IntravenousYoung AdultConceptsDeferred-treatment groupOpioid agonist therapyImmediate treatment groupHepatitis C virus infectionC virus infectionElbasvir-grazoprevirDrug useProbable reinfectionAgonist therapyHCV infectionViral recurrenceAdverse eventsVirus infectionChronic HCV genotype 1Double-blind trialGenotype 3 infectionTreatment-naive patientsHCV genotype 1Interferon-free HCV treatmentOngoing drug useVirologic responseHCV therapyHCV treatmentPrimary outcomeGenotype 1Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis
Rich JD, Beckwith CG, Macmadu A, Marshall BDL, Brinkley-Rubinstein L, Amon JJ, Milloy MJ, King MRF, Sanchez J, Atwoli L, Altice FL. Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. The Lancet 2016, 388: 1103-1114. PMID: 27427452, PMCID: PMC5504684, DOI: 10.1016/s0140-6736(16)30379-8.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsHepatitis BHepatitis CHepatitis, Viral, HumanHIV InfectionsHumansMass ScreeningPrisonersTuberculosisConceptsClinical careCommunity-based health careJail settingsHealth careDelivery of careCommunity-based treatmentProvision of treatmentHIV/AIDSPrison health careHepatitis BViral hepatitisMiddle-income countriesC virusClinical managementHigh-income countriesGeneral populationMedical careMental illnessInfectious diseasesOptimal deliverySubstance useCareTransmissible diseasesHIVTuberculosisThe perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia
Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, Taxman FS, El-Bassel N, Martin NK, Booth R, Stöver H, Dolan K, Vickerman P. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. The Lancet 2016, 388: 1228-1248. PMID: 27427455, PMCID: PMC5087988, DOI: 10.1016/s0140-6736(16)30856-x.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyHepatitis C virusIncident tuberculosis casesAgonist therapyC virusTuberculosis casesHIV transmissionEECA countriesAntiretroviral therapy coverageHIV transmission riskNew HIV infectionsInjection of opioidsTransmission of HIVSecondary preventionHIV infectionHIV incidenceSyringe programsHIVDrug useLarge burdenTransmission riskTherapyTuberculosisDrugsHigh levels
2015
Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum
Meyer JP, Moghimi Y, Marcus R, Lim JK, Litwin AH, Altice FL. Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. International Journal Of Drug Policy 2015, 26: 922-935. PMID: 26077144, PMCID: PMC4577454, DOI: 10.1016/j.drugpo.2015.05.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntiviral AgentsContinuity of Patient CareEvidence-Based MedicineHepatitis C, ChronicHumansMedication AdherenceConceptsEvidence-based interventionsHepatitis C care continuumInterferon-based HCV treatmentHepatitis C virus (HCV) treatmentHIV-specific interventionsOral treatment regimensVirologic response ratesC virus treatmentHIV treatment cascadeReal-world effectivenessPre-therapeutic evaluationEvidence-based strategiesHCV careHCV treatmentPeer-reviewed journalsTreatment cascadeTreatment initiationMedicine guidelinesTreatment regimensPatient populationTreatment adherenceCare engagementEligible studiesCare continuumHCV assessment
2012
Developing a Modified Directly Observed Therapy Intervention for Hepatitis C Treatment in a Methadone Maintenance Program: Implications for Program Replication
Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Developing a Modified Directly Observed Therapy Intervention for Hepatitis C Treatment in a Methadone Maintenance Program: Implications for Program Replication. The American Journal Of Drug And Alcohol Abuse 2012, 38: 206-212. PMID: 22242700, PMCID: PMC5573865, DOI: 10.3109/00952990.2011.643975.Peer-Reviewed Original ResearchConceptsSustained virologic responseEarly virologic responseMethadone maintenance treatmentHepatitis C treatmentSelf-administered therapyHepatitis C virusHCV treatmentVirologic responseAdherence supportWeek 12HCV treatment adherenceOpioid-dependent patientsBlood-borne infectionsMethadone-maintained patientsCompletion of treatmentCase-control studyMethadone maintenance clinicsMethadone maintenance programMental illness comorbidityConcurrent substance useC treatmentObserved therapyHCV genotypesHIV statusIllness comorbidity
2010
Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. The Lancet 2010, 376: 367-387. PMID: 20650518, PMCID: PMC4855280, DOI: 10.1016/s0140-6736(10)60829-x.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAntipsychotic AgentsAntitubercular AgentsAntiviral AgentsBacterial InfectionsComorbidityCriminal LawDrug InteractionsDrug Resistance, BacterialEvidence-Based MedicineHepatitis, Viral, HumanHIV InfectionsHumansMedication AdherenceMental DisordersNarcoticsPrisonersSubstance-Related DisordersTuberculosisConceptsSubstance use disordersDrug usersAntiretroviral therapyViral hepatitisHIV treatmentHealth of HIVPharmacokinetic drug interactionsSubstance use comorbiditiesMedication-assisted therapyEvidence-based treatmentsDrug-resistant strainsHealth-related outcomesHealth service deliveryInfectious complicationsMultiple comorbiditiesHIV infectionPsychiatric comorbidityPoor adherenceClinical managementCardiovascular diseaseInadequate prescriptionCongregate settingsDrug interactionsComorbiditiesHIV
2008
Clinical Outcomes of Hepatitis C Treatment in a Prison Setting: Feasibility and Effectiveness for Challenging Treatment Populations
Maru DS, Bruce RD, Basu S, Altice FL. Clinical Outcomes of Hepatitis C Treatment in a Prison Setting: Feasibility and Effectiveness for Challenging Treatment Populations. Clinical Infectious Diseases 2008, 47: 952-961. PMID: 18715156, PMCID: PMC4847716, DOI: 10.1086/591707.Peer-Reviewed Original ResearchConceptsSustained virological responseRate of prescriptionVirological responsePEG-RBVBaseline HCV RNA levelHepatic C virus infectionHCV genotype 1 infectionBaseline major depressionC virus infectionChronic HCV infectionHCV RNA levelsTreatment-naive patientsGenotype 1 infectionHepatitis C treatmentOutcome of treatmentUse of medicationsNewer mood stabilizersHCV infectionHIV infectionClinical outcomesMood stabilizersAntipsychotic medicationBlack raceClinical effectivenessMajor depression